Medical Technology and Evaluation Coursera Quiz Answers

Week 01: Medical Technology Assessment Environment Quiz Answers

Q1. Which of the following is a use a potential user of medical technology evaluation results?

  • Manufacturers.
  • Insurers.
  • Health care providers.
  • All of the above.

Q2. True or False: A medical technology evaluation is just a pricing project.

  • True
  • False

Q3. How can a new technology with lower costs lead to higher health care expenditures?

  • The technology will only reduce expenditures.
  • The technology is effective and used by a larger population than the current technology.
  • No new technologies have lower costs.
  • The technology has better outcomes compared to the current technology.

Q4. What is the regulatory reason that medical technology evaluation evidence is needed?

  • Only payment/reimbursement.
  • Venture capitalist investments.
  • Pricing.
  • Marketing approval and payment/reimbursement.

Q5. Which of the FDA approval phases occurs after FDA approval?

  • Phase IV
  • Phase III and IV
  • None
  • Phase I

Q6. True or False: Once approved a new drug can only be prescribed for what it was approved to treat.

  • True
  • False

Q7. Approximately what percent of new medical devices require a Pre-Market Approval (PMA)?

  • 0 percent
  • 100 percent
  • 90 percent
  • 10 percent

Q8. What is the next step after a drug is approved by the FDA?

  • File an NDA.
  • Conduct a clinical trial.
  • Get insurers to pay/reimburse.
  • Design the packaging.

Q9. What aspects of medical care is covered by Medicare Part A?

  • Outpatient services.
  • Inpatient hospital care.
  • Prescription drugs.
  • Patient out-of-pocket costs.

Q10. True or False: Patients may have higher cost-sharing obligations for the more expensive brand name version of a drug.

  • True
  • False

Week 02: Clinical Trials and Insurance Claims Data Quiz Answers

Q1. following is an example of an experimental design?

  • Patient survey
  • Case study
  • Observational study
  • Randomized controlled trial

Q2. Which of the following is not an alternative to randomization?

  • A placebo treatment.
  • Historical controls.
  • Systematic alternation of treatments.
  • Non-randomized concurrent controls.

Q3. Who is blinded in a double-blind trial design?

  • Patient and Investigator/Provider
  • Investigator/Provider and Statistician
  • Patient and Caregiver
  • Patient and Statistician

Q4. Which of the following elements is included in claims data?

  • Diagnoses and procedure codes.
  • Procedure codes and prices.
  • Prices and patient demographics.
  • All of the above.

Q5. Which of the following is not a benefit of claims data?

  • Includes physicians notes.
  • Large samples.
  • Includes all sources of care.
  • Diagnoses and procedures.

Q6. What are DRGs used for?

  • FDA approval.
  • Medicare inpatient billing/payment.
  • Measuring QALYs.
  • Prescription drug reimbursement.

Q7. What population is covered by Medicare?

  • Ages 65 and older and disabledThe working population
  • Anyone
  • None of the above

Q8. Which of the following is not a potential source of bias?

  • Currency
  • Reporting
  • Detection
  • Selection

Q9. Which of the following questions can a meta-analysis answer?

  • What is the direction of the effect?
  • What is the size of the effect?
  • Is the effect consistent across studies?
  • All of the above

Q10. True or False: claims data can only be used for policy research.

  • True
  • False

Week 03: Peer-graded Assignment: You Are The Consultant

Click here to Download

Week 04: Methodological Approaches and Considerations Quiz Answers

Q1. If an assessment is being conducted to support the case for payment/reimbursement
who is the audience?

  • The Food and Drug Administration (FDA)
  • Physicians
  • Insurers or Payers
  • Venture capitalists

Q2. What is the denominator of the incremental cost-effectiveness ratio (ICER)?

  • Indirect costs.
  • Future costs.
  • Benefits of the new technology.
  • Difference in benefits.

Q3. True or False: Only cost-effective technologies ICERs can be graphed on the cost-effectiveness plane.

  • True
  • False

Q4. What is Bayes rule used for?

  • Measuring quality of life (QoL).
  • Randomization in a clinical trial.
  • Incorporating new information to determine a probability of interest.
  • Graph an ICER.

Q5. Future values of which of the following can be discounted to present value?

  • Direct medical costs.
  • Indirect costs.
  • Quality adjusted life years (QALYs).
  • All of the above.

Q6. The expected value of a health outcome is calculated by multiplying the outcome measure by what?

  • Quality of Life (QoL).
  • The discount rate.
  • Direct costs.
  • The probability of the outcome.

Q7. The results of a Monte Carlo simulation can be used to determine the information about the results of an evaluation?

  • Mean and variance of the results.
  • The mean result.
  • The variance of the result.
  • None of the above.

Q8. True or False: A Markov model allows for modeling the progression of the disease over time.

  • True
  • False

Q9. Which of the following is not a source of uncertainty?

  • Future costs.
  • Randomness in medical cost.
  • Randomness in health outcomes.
  • Statistical variation in results.

Q10. In a sensitivity analysis, how many variables can be tested?

  • Only one
  • None
  • One or more
  • Only two

Next Course Quiz Answers >>

Healthcare Marketplace Capstone

<< Previous Course Quiz Answers

Pharmaceutical and Medical Device Innovations

All Course Quiz Answers of Healthcare Marketplace Specialization

Course 01: Healthcare Marketplace

Course 02: Healthcare Delivery Providers

Course 03: Pharmaceutical and Medical Device Innovations

Course 04: Medical Technology and Evaluation

Course 05: Healthcare Marketplace Capstone

Team Networking Funda
Team Networking Funda

We are Team Networking Funda, a group of passionate authors and networking enthusiasts committed to sharing our expertise and experiences in networking and team building. With backgrounds in Data Science, Information Technology, Health, and Business Marketing, we bring diverse perspectives and insights to help you navigate the challenges and opportunities of professional networking and teamwork.

Leave a Reply

Your email address will not be published. Required fields are marked *